Horizon Science has successfully closed its fourth round of financing which will drive the development of their leading polyphenol extracts.
With a broad portfolio of extracts supported by robust intellectual property, Horizon Science specializes in the management of risk factors related to metabolic syndrome aiming to assist in the management of chronic disease such as diabetes.
Strong clinical results have demonstrated that polyphenol extracts reduce blood glucose and insulin levels in carbohydrate-based diets. With powerful pre-clinical results showing high efficacy in weight and fat management, the company is now poised to take one of its key extracts in to clinical trials.
Arvind Sridharan, CEO of Horizon Science, believes that with two products in market and a promising pipeline in clinical phase, the funding validates the support for the company’s IP, its commercial viability and global relevance.
“Diseases related to metabolic syndrome are rising and it is quickly becoming a leading public health problem throughout the world and a challenge for the future. Horizon Science’s intellectual property can help the consumer health industry access scientifically advanced ingredients that may reduce and prevent obesity, diabetes and related lifestyle diseases,” he said.